ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
Study Type
OBSERVATIONAL
Enrollment
360
Michael Garron Hospital
Toronto, Ontario, Canada
RECRUITINGSt. Joseph's Health Centre
Toronto, Ontario, Canada
RECRUITINGUniversity Health Network
Toronto, Ontario, Canada
RECRUITINGRate of ctDNA Detection
The percentages of pre-operative and post-operative ctDNA detection in patients with T1-T4N0 (T3, T4 multifocal) NSCLC will be estimated together with their Clopper-Pearson exact 95% CIs.
Time frame: Up to 24 Months
Relapse Free Survival
Relapse free survival (RFS) will be estimated using the Kaplan-Meier method and compared using the logrank test among patients with and without detectable ctDNA pre- or post-operatively.
Time frame: Up to 36 Months
Overall Survival
Overall survival (OS) will be estimated using the Kaplan-Meier method and compared using the log-rank test between patients with and without detectable ctDNA pre- or post-operatively.
Time frame: Up to 36 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.